BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane ...
Bayer (OTCPK:BAYRY) said that phase 3 data on its experimental MRI contrast agent gadoquatrane met primary and secondary endpoints in phase 3 trials. The QUANTI studies examined gadoquatrane at a ...
Researchers at the University of East Anglia have developed cutting-edge imaging technology to help doctors better diagnose and monitor patients with heart failure. The state-of-the-art technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback